• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


New ms drugs

Quote

Anonymous

Guest
For all you current Tysabri reps. Got called for an interview to sell Tysabri. I am concerned because of the new Roche competitor coming out. Do you guys think it will wipe out Tysabri? Has the company addressed this, what are you current reps' thoughts? Serious replies only please! Thanks
 




Anonymous said:
For all you current Tysabri reps. Got called for an interview to sell Tysabri. I am concerned because of the new Roche competitor coming out. Do you guys think it will wipe out Tysabri? Has the company addressed this, what are you current reps' thoughts? Serious replies only please! Thanks
Click to expand...

If you are referring to Firategrast, I wouldn't worry all that much. It's basing its hope on having a half life in one's system of 4.5 days vs 11 days for Tysabri and thus will be less likely to have the side effects like the deadly PML.

While that feature may look nice, neuros not involved in the study don't seem to be all that impressed with the initial findings on how it helps MS.
 




u should be more concerned about the micromanaging you will be subjected to at Biogen. Bonuses have not been great last few years and management thinks that a big pharma approach is best and it is reflected in the experience level of the reps they are bringing in.

...just saying !
 




Anonymous said:
u should be more concerned about the micromanaging you will be subjected to at Biogen. Bonuses have not been great last few years and management thinks that a big pharma approach is best and it is reflected in the experience level of the reps they are bringing in.

...just saying !
Click to expand...

Agreed! If you think you are entering a biotech culture, think again. I hope you like 2 day ride alongs.
 








Top Bottom
Back
Quote